Summary
Pelizaeus-Merzbacher disease (PMD) is a rare inherited condition that affects the brain and spinal cord. It is a type of hypomyelinating leukodystrophy, which means the body has trouble making myelin, the protective covering around nerves. PMD happens because of a genetic change in the PLP1 gene, which causes problems with how myelin forms.
There are several forms of PMD, and symptoms can range from mild to severe. Symptoms may include problems with movement, muscle tone, speech, and development. PMD affects boys more often than girls. There is no cure, but therapies and medical care can help improve development, comfort, and quality of life.
Description
PMD affects the central nervous system (CNS), which includes the brain and spinal cord. The CNS sends messages throughout the body using nerve fibers. These nerves are covered in myelin, a fatty layer that helps signals travel quickly and smoothly.
In PMD, a change in the PLP1 gene makes it hard for myelin to form correctly. When myelin is missing or damaged, nerve signals slow down or stop, leading to the symptoms of PMD.
There are different forms of PMD based on when symptoms begin. These forms vary in how severe the symptoms are. Common symptoms include trouble walking, talking, and coordinating movements.
- Connatal PMD: Connatal means at birth, so the symptoms of this form of PMD start very early in life. Early signs may include poor feeding or slow motor development. Children with connatal PMD may never develop the ability to walk, have difficulty using their arms and hands, and may never learn to talk, but they may be able to understand what is said. They will have very low muscle tone (hypotonia), where their muscles feel floppy, and they may get tired more easily. Infants and children will also have difficulties with balance and coordination, also known as ataxia. Infants and children can also have rapid and uncontrollable eye movements, called nystagmus. Connatal PMD is a life-limiting form of the disease.
- Classic PMD: This is the most common type of PMD, and typically presents around 1 year of age. Some children develop the ability to walk, but often need an assistive device such as a walker, and eventually lose the ability to walk as their disease progresses. They will often learn and be able to talk, but their speech is dysarthric which is slow and difficult to understand. Classic PMD can be associated with a shorter lifespan. People with classic PMD have lived to be in their 60s and 70s.
- Transitional PMD: Timing of symptoms and severity of symptoms is in between the conatal and classic forms of PMD. Progression of the disease is typically faster than classical but slower than connatal PMD.
- Spastic paraplegia 2 (SPG2): This is a milder form of PMD in which a child may meet early developmental milestones, but have progressive difficulty with coordination and walking over time as the disease progresses. These patients can talk, but speech may be slow. Patients with complicated SPG2 may have cognitive impairment, bladder spasticity, ataxia, nystagmus, in addition to spastic paraplegia. Lifespan may be normal.
- Other PLP1 gene related disorders: These disorders result from different variants of the same gene (allelic disorders) on the X chromosome. Other less common forms of PMD also caused by changes in the PLP1 gene include the conditions below. For more information see https://www.ncbi.nlm.nih.gov/books/NBK1182/ :
- PLP1 null syndrome: Infants and children typically less severe symptom compared to other PMD types. Symptoms include ataxia, developmental delays, spastic paraplegia (or muscle tightness that mostly affects the legs) and peripheral neuropathy (or nerve dysfunction). Children with this type of PMD typically have an easier time walking than patients with classic PMD though may lose motor skills over time.
- Hypomyelination of early myelinating structures (HEMS): A form of PMD that often leads to a combination of autonomic dysfunction such difficulty with controlling urination, ataxia, and nystagmus
Signs and Symptoms
PMD symptoms vary widely. Over time, children may lose skills they once had and develop new symptoms as the disease progresses.
Common clinical symptoms of the disease can include:
- Nystagmus (involuntary eye movements)
- Hypotonia (decreased muscle tone)
- Spasticity (stiffness or increased muscle tone; hypotonia progresses to spasticity)
- Titubation (head-bobbing)
- Stridor (high-pitched wheezing sound) and/or vocal paralysis in severe cases
- Feeding difficulties (feeding themselves, eating by mouth, coughing and choking while eating, difficulty swallowing)
- Delayed developmental milestones including sitting late, walking late, talking late
- Difficulties with communication (speech and comprehension)
- Ataxia of the limbs (difficulty coordinating movements of arms and legs)
- Cognitive impairment (thinking, memory)
Other clinical features include:
- Seizures
- Dystonic posturing (abnormal fixed posture)
- Athetotic movements (involuntary writhing)
- Cortical visual deficits (difficulty seeing)
- Difficulty hearing
- Bowel and bladder problems
- Drooling
- Teeth grinding
- Sleep difficulties
Symptoms may appear in infancy, such as poor feeding or slow motor development. Some children lose skills over time. Long-term effects can include difficulty with movement, breathing, and communication.
Causes
PMD is caused by a genetic change in the PLP1 gene (protelopipic protein) that makes it difficult to form myelin correctly. PMD and PLP1-related disorders are X-linked disorders. At birth females receive two X chromosomes while males receive one X and one Y chromosome. If females inherit the altered gene on one of the X chromosomes, the other X chromosome can compensate for the defect. However, if males inherit the defected gene, he will have PMD since there is not an extra X chromosome to counteract the disease-causing gene.
Females who carry a PLP1 genetic change may be unaffected or experience less severe symptoms of the disorder, including muscle stiffness (spasticity). Females with one PLP1 genetic change have an increased risk of experiencing dementia later in life.
There are multiple different types of genetic changes that can affect the PLP1 gene in different ways. Deletions of the gene, duplications of gene, and null mutations often result in milder forms of the disease. Missense mutations, which change the way the protelopipic protein is made, often causes the more severe form of PMD.
Each male child born to a carrier mother has a 50/50 chance of being affected with PMD, and each female child born to a carrier mother has a 50/50 chance of being a carrier. If a male is not affected with PMD, he cannot pass this disease on to his children. Males with PMD are not likely to have children. Some cases of PMD are not inherited and are causes by genetics changes that are new in the child, called de novo mutations.
It is important to remember that PMD is not caused by anything a parent does during pregnancy.
Laboratory Investigations
Tests used to diagnose and monitor PMD include:
- Genetic testing: To confirm genetic changes in the PLP1 gene
- Neuroimaging (MRI of the brain): Shows abnormal white matter due to poor myelin development (hypomyelination)
- Neurological exam and developmental tests: To check motor skills, language skills, muscle tone, and coordination
These tests are usually done at diagnosis. MRI of the brain and neurological evaluations may be repeated to track the disorder’s progress.
Additional tests that may be helpful in PMD management:
- Nerve conduction studies to evaluate nerve dysfunction, especially in PLP1-null syndrome
- EEG if there is a concern for seizures, especially in severe PMD subtypes
Treatment and Therapies
There is no cure for PMD. Treatment focuses on managing symptoms and improving comfort, mobility, communication, and nutrition. Care plans are individualized.
- Physical therapy: To improve strength, flexibility, and reduce stiffness
- Occupational therapy: To support daily function
- Speech and language therapy: To support communication
- Orthopedics: To support scoliosis (abnormal curving of the spine), mobility and bracing of joints for low tone
- Feeding therapy and nutritional support: To evaluate safety of swallowing, and support adequate nutrition
- Anti-seizure medications: If seizures are present
- Respiratory support: evaluate and support for safe breathing
- Mobility aids and assistive devices: To help with function, independence, and communication. Examples include wheelchairs or communication, leg braces, and communication boards
Key subspecialists that often form the care team of a child with PMD include:
- Neurologist
- Pulmonologist
- Ophthalmology (eye specialists)
- Physical, occupational, and speech and language therapists
- Gastroenterology, nutritionist/dietitian
- Audiologist (to evaluate hearing)
- Orthopedics
Outlook
PMD is a lifelong and progressive condition, which means symptoms will get worse over time. It is not possible to grow out of PMD. While the severity depends on the subtype and age of onset, most children with PMD will face significant disability and will require support for everyday activities. PMD can be a life-limiting illness. However, some children with PMD can live into their teenage years or adulthood, depending on the severity and type.
Symptomatic supportive care will help to optimize quality of life in individuals with PMD but cannot stop the disease progression. Most children with PMD will require extra support at home and school for activities of daily living. Most children with PMD will not live independently. Individuals with PMD that has significantly progressed may require home nursing support or palliative care.
Resources
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
This family driven foundation will proactively serve those affected by Pelizaeus-Merzbacher Disease (the PMD community) by supporting programs of education, research, service and advocacy. We are dedicated to providing patients and their families with information about their disease and assistance in identifying sources of medical care, social service, and genetic counseling; establishing a communications network among families; increasing public awareness and acting as an information source for health care providers; and promoting research into causes, treatment, prevention and cure of PMD.
United Leukodystrophy Foundation
OUR MISSION is to provide support to the leukodystrophy community and enable platforms to accelerate improving patient quality of life and finding cures.
OUR VISION is to meet the needs of patients and families, whether newly diagnosed or living with a leukodystrophy. Through unified collaboration with advocacy groups, medical and research professionals, and pharma/biotech companies, we provide support, networking, and education to help navigate the journey of the disease.
Research
ClinicalTrials.gov for PMD (birth to 17 years)
These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
For more information about participation in clinical trials, check out our education hub on the topic here.
Family Stories
The PMD Foundation shares family stories to raise awareness and connect the PMD community.
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
- Garbern JY. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci. 2007;64:50-65.
- Hobson GM, Garbern JY. Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders. Semin Neurol. 2012;32:62–67.
- Inoue, K. Pelizaeus-Merzbacher disease: molecular and cellular pathologies and associated phenotypes. Adv Exp Med Biol. 2019;1190:201-216.
- Khalaf, G., Mattern, C., Begou, M., Boespflug-Tanguy, O., Massaad, C., & Massaad-Massade, L. (2022). Mutation of proteolipid protein 1 gene: From severe hypomyelinating leukodystrophy to inherited spastic paraplegia. Biomedicines, 10(7), 1709.
- National Organization for Rare Disorders. Pelizaeus-Merzbacher Disease [Internet]. Danbury (CT): National Organization for Rare Disorders (US); 2023. Available from: https://rarediseases.org/rare-diseases/pelizaeus-merzbacher-disease/
- Osório, M. J., & Goldman, S. A. (2018). Neurogenetics of Pelizaeus–Merzbacher disease. Handbook of clinical neurology, 148, 701-722.
- Singh R, Samanta D. Pelizaeus-Merzbacher Disease. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560522/
- van der Knaap MS, Wolf NI. Leukodystrophies: clinical overview and advances in diagnosis and treatment. Nat Rev Neurol. 2019 Jul;15(7):412–429. doi:10.1038/s41582-019-0222-8. PMID: 31197173.
- Wolf NI, van Spaendonk RML, Hobson GM. PLP1-Related Disorders. 1999 Jun 15 [updated 2025 Jun 12]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1182/
- Perplexity AI, Inc. Perplexity [Internet]. San Francisco (CA): Perplexity AI, Inc.; 2025 [cited 2025 Oct 24]. Available from: https://www.perplexity.ai
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory